Zobrazeno 1 - 10
of 301
pro vyhledávání: '"recombinant zoster vaccine"'
Autor:
François Roman, Wivine Burny, Maria Angeles Ceregido, Béatrice Laupèze, Stéphane T Temmerman, Lucile Warter, Margherita Coccia
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 715-729 (2024)
Introduction The use of novel adjuvants in human vaccines continues to expand as their contribution to preventing disease in challenging populations and caused by complex pathogens is increasingly understood. AS01 is a family of liposome-based vaccin
Externí odkaz:
https://doaj.org/article/81dc6633736e41b888d3b814f3660234
Autor:
Ru Han, Peter San Martin, Nurilign Ahmed, Adriana Guzman-Holst, Ahmed Mohy, Thatiana Pinto, Bruna de Veras, Jorge A. Gomez, Gyneth Lourdes Bibera, Désirée A. M. van Oorschot
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 4, Pp 761-778 (2024)
Abstract Introduction Herpes zoster (HZ) can cause substantial patient morbidity and lead to large healthcare costs. However, the disease burden of HZ in Southeast Asia may be underestimated. This study aimed to estimate the public health burden of H
Externí odkaz:
https://doaj.org/article/425441d1f42a40d5b7fd86b89e37ad64
Autor:
Maxime Hentzien, Fabrice Bonnet, Enos Bernasconi, Emmanuel Biver, Dominique L. Braun, Aline Munting, Karoline Leuzinger, Olivier Leleux, Stefano Musardo, Virginie Prendki, Patrick Schmid, Cornelia Staehelin, Marcel Stoeckle, Carla S. Walti, Linda Wittkop, Victor Appay, Arnaud M. Didierlaurent, Alexandra Calmy
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background The burden of herpes zoster (shingles) virus and associated complications, such as post-herpetic neuralgia, is higher in older adults and has a significant impact on quality of life. The incidence of herpes zoster and post-herpeti
Externí odkaz:
https://doaj.org/article/3f8091d417ad43dbb2cb4768c4041a15
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
The recombinant zoster vaccine (RZV) is included in the Spanish National Immunisation Programme for adults 65 years of age (years), with a potential progressive catch-up program for adults 66–80 years, starting with 80 years. However, the risk of h
Externí odkaz:
https://doaj.org/article/e3f807443dce4a85a5d6b89e6c3dd195
Autor:
Diana Alexandra Echeverria Proano, Fengcai Zhu, Xiaodong Sun, Jesús Zoco, Jyoti Soni, Neeraj Parmar, S. Omar Ali
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Phase III multi-country studies (ZOE-50/70) demonstrated that the adjuvanted recombinant zoster vaccine (RZV) was well tolerated and prevented herpes zoster (HZ) in healthy ≥ 50-year-olds, with a vaccine efficacy (VE) > 90% across age groups. These
Externí odkaz:
https://doaj.org/article/378899e3d99746fbae93898ecd90c44b
Autor:
Ana Florea, Lina Sy, Lei Qian, Bradley Ackerson, Yi Luo, Jun Wu, Yanjun Cheng, Jennifer Ku, Leticia Vega Daily, Harpreet Takhar, Jeannie Song, Elizabeth Chmielewski-Yee, O’Mareen Spence, Harry Seifert, Driss Oraichi, Hung Fu Tseng
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTWe evaluated the vaccine effectiveness (VE) of two doses of recombinant zoster vaccine (RZV) against herpes zoster (HZ) and postherpetic neuralgia (PHN) in Chinese adults at Kaiser Permanente Southern California (KPSC). Chinese KPSC members w
Externí odkaz:
https://doaj.org/article/d183bd06668d4f9b85c20fcf2d7ac175
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ryuhei Ishihara, Ryu Watanabe, Mayu Shiomi, Masao Katsushima, Kazuo Fukumoto, Shinsuke Yamada, Tadashi Okano, Motomu Hashimoto
Publikováno v:
Biomolecules, Vol 14, Iss 7, p 739 (2024)
The varicella-zoster virus (VZV) is a human neurotropic herpes virus responsible for varicella and herpes zoster (HZ). Following primary infection in childhood, VZV manifests as varicella (chickenpox) and enters a period of latency within the dorsal
Externí odkaz:
https://doaj.org/article/6955efa3942c4b178b18cc02bce3a4b2
Publikováno v:
Zhongguo gonggong weisheng, Vol 39, Iss 8, Pp 1043-1048 (2023)
ObjectiveTo construct a prediction model for the intention of accepting recombinant zoster vaccine(RZV) vaccination among community residents based on reasoned action approach for promoting RZV vaccination in the population. MethodsTotally 1 480 atte
Externí odkaz:
https://doaj.org/article/f6716949d6b543ab863c8574742b848c
Autor:
Joshua M. Garcia, Ramez I. Haddadin
Publikováno v:
IDCases, Vol 37, Iss , Pp e02070- (2024)
Purpose: Immunizations have long been pivotal in preventing diseases like HZ (herpes zoster), caused by VZV (varicella zoster virus). This study aims to evaluate the efficacy and safety of the RZV (recombinant zoster vaccine) compared to the ZVL (zos
Externí odkaz:
https://doaj.org/article/3b4ad9b0838c4ad79bdc8e138a2a56f0